Sinobioway Group Co., Ltd.

[Drug Name]

Generic name: Mouse Nerve Growth Factor for Injection

Brand name: NOBEX^®

[Product advantage]

1. NOBEX^® is the best choice for nerve nutrition, and can be use to promoting nerve regeneration and function reconstruction;

2. NOBEX^® was launched in 2003, safety and effectiveness have already been proved by millions of clinical practices.

3. NOBEX^® is the exclusive direct treatment drug for injured neurons with high putiry, high biological activity and high stability, which can be efficiently recover exercise and sensory functions, which can efficiently recover exercise and sensory functions in patients, reduce disability rate, and offer high quality life to the patients.

4. NOBEX^® is the first therapeutic drug for neural injury in the world commercialized by Chinese from the outcome of a Nobel Prize in Physiology and Medicine.

[Character]

NOBEX^® is white, freeze-dried free-flowing powder. The dissolved solution is transpatent, free from visible foreign particles, muddy and precipitate.

[Indication]

Peripheral neuropathy induced by n-Hexane, Promoting recovery of injured nerve.

[Off-label use]

1. Optic nerve contusion;

2. Diabetic foot;

3. Neurology: Peripheral neuropathy, Parkinson's disease, Alzheimer disease, Craniocerebral injury, Stroke, Diabetic peripheral neuropathy, Guillian-Barre syndrome, Spinal cerebellar ataxia Type 3;

4. Orthopedics: Spinal Cord injury, Acute Myelitis, Fracture;

5. Pediatrics: Hypoxic-ischemic encephalopathy, Neonatal cerebral palsy, Autism spectrum disorder;

6. Burns;

7. Ophthalmology: Keratohelcosis, Glaucoma;

8. Others:

[Dosage & Administrators]

Intramuscular injection with one dose dissolved in 2 ml water for injection, one dose daily and four weeks as a treatment cycle. Frequent continuous doses can be applied as per the doctor’s prescribing based on severity disease for each patient.

[Adverse reactions]

1. No serious adverse reactions. Transient elevation of transaminase for few patients was observed during the clinical trials.

2. The most frequent adverse reactions were pain at the injection site which occurred in 85% of patients, pain at lower limbs of injection site which occurred in 29% of patients. It does not need any specific treatment generally, occasionally severe symptom needed orally analgesic remedy.

3. The less frequent adverse reactions observed in clinical studies include: dizziness and insomnia. These incidences were no evident difference compare with the placebo group.